Aurinia Pharmaceuticals (AUPH) Stock
Kidney disease biotech with approved lupus therapy. Here's the price, business snapshot, and what's worth knowing about Aurinia Pharmaceuticals in July 2026.
Aurinia Pharmaceuticals (AUPH) is a clinical-stage biotechnology company focused on therapies for autoimmune and inflammatory kidney disorders. Its lead product, voclosporin (marketed as Lupkynis), targets lupus nephritis and represents the company’s primary commercial revenue driver following regulatory approvals. Investors should watch sales uptake, pricing and reimbursement decisions, and the company’s ability to expand indications or develop next-generation candidates. Financially, Aurinia is a smaller-cap biopharma (market capitalisation around $1.56bn) so trading can be volatile and dependent on clinical data, regulatory milestones and partnering activity. Key risks include competitive treatments, uncertain long-term commercial adoption, regulatory hurdles and the typical clinical development risks. This summary is for general educational purposes only and not personalised investment advice; potential investors should consider their objectives and seek independent advice before investing.
Stock Performance Snapshot
Financial Health
Aurinia Pharmaceuticals is showing good revenue and profitability, indicating a strong financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring AUPH
Rare Kidney Disease Treatments | A Market Overview
The FDA's expanded approval of Travere's FILSPARI validates the growing market for rare nephrology treatments. This milestone creates positive momentum for biopharma companies developing innovative therapies for underserved kidney conditions.
Published: 14 April 2026
Explore BasketOncology Repurposing: Could Autoimmune Buyouts Surge?
Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published: 24 March 2026
Explore BasketTYK2 Inhibitors: Might Oral Drugs Rule Autoimmune?
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published: 7 January 2026
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: 3 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Approved therapy traction
Voclosporin’s commercial uptake is central to Aurinia’s near-term outlook; sales and reimbursement trends are worth watching, though outcomes can vary.
Pipeline and expansion
Clinical studies and potential label expansions could meaningfully change prospects, but development and regulatory risks remain.
Market and competition
Competitive immunosuppressants and payer decisions influence long-term adoption; investors should balance opportunity with typical biotech volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
